Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Maintenance After Allo-SCT in Ph+ ALL
NCT01310010Phase 2Completed
- Sponsor
- GETH-TC
- Start
- Apr 2010
- Primary completion
- Oct 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by GETH-TC. Primary endpoint: Disease Free Survival at 2 years. Started Apr 2010; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01310010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310010.